Huma to provide best-in-class digital clinical trials solutions through landmark acquisition of Alcedis
In January we acquired iPLATO, expanding our reach to more than 26 million people in its network. Plus, with a proven ability to increase the use of healthcare services by up to 65%, iPLATO’s digital software, myGP, helps us to accelerate digital-first delivery of healthcare and research and bring ‘hospitals at home’ and decentralized clinical trials to even more customers.
In February we announced the exciting results of a study conducted alongside BMC (BioMed Central) Family Practice. With a 40% reduction in time spent reviewing patients, the study proved that app-based remote monitoring of patients could free up vital resources in terms of clinical team’s time, allowing a better reallocation of services.
Based on this finding, for every 100 patients, four fewer clinicians are required to monitor them remotely.
In March, we announced our pioneering partnership with the world-leading pharmaceutical company, AstraZeneca, which is truly visionary in its embrace of digital technologies to improve medicines discovery and development. Rather than build these capabilities in-house, AZ has partnered with us to become their digital arm to deploy digital health tools to engage patients in care and treatment, and advance diversity through hybrid and decentralized clinical trials.
<div class="resources-cta">Read more</div>
myGP (iPLATO) reached more than 2.5 million users in a single week in April 2022, a huge milestone for our new acquisition. Instrumental in increasing uptake of NHS services, including IAPT services, cancer screenings and health checks, myGP results in up to 65% higher uptake of services communicated through the app.
Considered the ‘Nobel-Prize of pharma’, this accolade, (awarded in May 2022 for ‘International Best Digital Health Solution’) marks our second Prix Galien Award win for our ‘hospital at home’ technology, which almost doubles clinical capacity and reduces readmissions by connecting patients to their care teams through a smartphone app.
In June, we partnered with Xyla Elective Care, a national provider of NHS England-funded elective services, to deliver tech-enabled virtual wards using Huma’s award-winning remote patient monitoring platform. Together, we’re supporting Xyla Elective Care’s network of more than 50 trusts and CCGs and 90,000+ patients.
Sifted ranked the most promising startups across the UK in a weighted selection of new entries, older faces and fast-growing hits. Huma were proud to be earn the accolade ‘tech partner to watch’.
In August we were thrilled to see The Times report on the impact of Huma, including how our medical device platform helped patients like David Watkins (69), by preventing hospital readmissions and getting people home sooner using data collected through our app.
Huma’s technology was used in a fully virtual atrial fibrillation trial by Stanford Medicine and Bayer, in which 94% of patients were recruited in just 12 days. In September, we announced the results of the study, named DeTAP. The results included:
Our CEO, Dan Vahdat, joined leading experts at the World Economic Forum to discuss how start-ups are breaking new ground in biotech and changing the way we interact with the world, but also how the sector can earn trust, scale successfully and spot the brightest innovations.
In November, we attended healthcare's #1 innovation event, HLTH in Las Vegas. We connected with healthcare leaders from across the globe, gained a wealth of insight and shared our visions for advancing predictive, proactive health for all.
In December we hosted two live webinars, with experts from the NHS, Stanford University Medical Center, University of Cambridge School of Clinical Medicine, Pfizer and AstraZeneca, sharing our knowledge on best practice for virtual wards and engagement in clinical trials.
3000+ hospitals and clinics supported across Huma platforms to secure the most sustainable impact for patients1
Our platform can almost double clinical capacity and reduce readmission rates by >30%3
Huma's digital-first health platforms support a network of 27m patients1
Over 1 million devices have been shipped in support of our projects and we know what it takes to deploy at scale1
Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4
Selected as one of 'The Most Important Healthcare Design of 2021' by Fast Company5
Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4
Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4
Room 123, 13th Floor
Shanghai Tower
No. 501 Yincheng Middle Road
China
For all China enquiries
(DACH-Region)
Huma Therapeutics GmbH
Rundfunkplatz 2
80335 Munich
For all enquiries
